The Department of Health Care Access and Information (HCAI) was appropriated fifty million dollars ($50,000,000) to support the development of three low-cost interchangeable biosimilar insulin products with one or more partners under the California Affordable Drug Manufacturing Act of 2020. This is the first phase of the CalRx Biosimilar Insulin Initiative (Initiative).

Bid Protests Not Available